Cancer research
Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma.
W Frank Lenoir, Michael R McKeown, Giulia Giorgetti, Marek J Kobylarz, Tamara D Hopkins, Wayne L Glore, Michelle G Shum, Yaretzi Calderón, Jessica Encinas Mayoral, Luis A Carvajal, Kameron R Mori, Jun Li, Hua Gao, Yupeng Zheng, Zhihua Ma
Published: 202510.1158/0008-5472.CAN-25-3440
Abstract
The oncogenic transcription factor (TF) IRF4 is a currently undrugged universal multiple myeloma (MM) dependency. Using transcriptional regulatory network (TRN) mapping, an unbiased multi-omic target ID approach, we identified the coactivator lysine…
Preview only. Read the full abstract at the source